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A novel coronavirus (CoV) was quickly recognized as the cause of a cluster of severe pneumonia cases in China around December 2019. Now known as coronavirus disease (COVID-19), the epidemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus rapidly surged to pandemic proportions, with sweeping global public health and economic consequences. In this review, we aim to discuss the emergence of this novel CoV in the context of the virus characteristics and pathogenesis, transmission, clinical syndrome, and potential therapeutics or vaccines.

COVID-19 Virology
=================

CoVs are large RNA viruses that are endemic among bats globally. These bat viruses are known to readily recombine and present an ever-present potential to jump host species, allowing for emergence into novel hosts ([@bib1]). Four seasonal human CoVs (hCoVs) circulate yearly as mild "common cold" viruses causing upper respiratory symptoms: OC43, HKU1, NL63, and 229E. In addition, three novel CoVs have emerged as zoonotic human infections in the past 17 years; SARS-CoV, Middle East respiratory syndrome CoV (MERS-CoV), and the 2019 novel CoV (SARS-CoV-2) ([@bib2]) have each been associated with lower respiratory symptoms, progressing in a subset of individuals to acute respiratory distress syndrome (ARDS) and death.

The full genome sequence of SARS-CoV-2 shares some striking similarities to SARS-CoV ([@bib2]). SARS-CoV-2 is a member of the betacoronavirus 2b clade that includes the original SARS-CoV (sharing 79.5% sequence homology), as well as a more distant seasonal hCoV, OC43 ([@bib3]). SARS-CoV-2 also uses the same human host receptor as SARS-CoV for viral entry, angiotensin converting enzyme 2 ([Figure 1](#fig1){ref-type="fig"}) ([@bib3]). Although many questions about the increased pathogenicity of emergent zoonotic CoVs remain unanswered, the receptors used for host cell entry play a pivotal role. The spike glycoprotein of the virus is responsible for receptor binding and entry, and is the main determinant of host range. Both SARS-CoV and SARS-CoV-2 use angiotensin converting enzyme 2, whereas MERS-CoV uses DPP4 (dipeptidyl peptidase 4). Interestingly NL63, an hCoV that also uses angiotensin converting enzyme 2 as the host receptor, but typically causes mild upper respiratory disease, was the cause of a cluster of severe pediatric pneumonias in China in 2018, during which half of the patients were identified with viruses containing a specific substitution in the spike glycoprotein that enhanced binding to and entry via angiotensin converting enzyme 2 ([@bib4]). The same substitution does not have a role in the current COVID-19 outbreak, as SARS-CoV-2 has a structurally dissimilar spike glycoprotein and recognizes a different epitope of angiotensin converting enzyme 2 ([Figure 1](#fig1){ref-type="fig"}). Nonetheless, the acquisition of "minor" changes in the spike glycoprotein may contribute to the increased virulence of zoonotic CoVs. The SARS-CoV-2 spike binds angiotensin converting enzyme 2 with 10- to 20-fold-higher affinity than SARS-CoV spike, which may affect transmission or pathogenesis ([@bib5]).
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COVID-19 Pathogenesis
=====================

The severe respiratory compromise of SARS and COVID-19 are likely mediated by mechanisms, including a combination of direct cytopathic effects, immune-mediated pathology, and downregulation of angiotensin converting enzyme 2 within the lung ([@bib6]). Severe pulmonary damage in SARS was associated with increased inflammatory cytokines, recruitment of macrophages and neutrophils to the lungs, and higher viral titers ([@bib7]). Autopsy data showed histologic evidence of acute lung injury with denuding of the ciliated epithelia, diffuse alveolar damage, and hyaline membrane formation indicative of ARDS ([@bib7]). A pathology report from a single patient with COVID-19 shows similar histology ([@bib8]). Angiotensin converting enzyme 2 is normally expressed on type II pneumocytes and the apical surface of ciliated airway epithelial cells, serving as an entryway for direct cytopathology ([@bib9]). Functionally, angiotensin converting enzyme 2 acts as a negative regulator of angiotensin II in the renin--angiotensin system, potentially providing a protective role in ARDS by promoting antiinflammatory and antifibrotic effects ([@bib9]). In animal models, downregulation of angiotensin converting enzyme 2 increased lung pathology (pulmonary edema and acute lung failure), which was restored by supplemental recombinant angiotensin converting enzyme 2 ([@bib9]). SARS-CoV infection prompted shedding of the angiotensin converting enzyme 2 ectodomain, removing the catalytic function of angiotensin converting enzyme 2 and possibly potentiating the development of ARDS ([@bib6]). This shedding can be induced by the SARS-CoV spike glycoprotein alone, and is more rapid than the shedding elicited by the spike glycoprotein of NL63 (seasonal hCoV) ([@bib6]). It can be hypothesized that the spike glycoprotein of SARS-CoV-2, with its structural similarity and higher affinity binding to angiotensin converting enzyme 2, provokes a similar mechanism of lung pathology leading to ARDS with severe COVID-19.

The overall case fatality rates for SARS and MERS was 10% and 35%, respectively ([@bib10]). Although crude case fatality is hovering around 4% for COVID-19, this estimation is exaggerated by limitations in testing and underestimated by the lag in deaths, with the adjusted case fatality rate estimated to be between 0.25 and 3% ([@bib11], [@bib12]). The three emergent CoV infections share the trend of high mortality rates among older adults. The mortality rate was \>50% for individuals over 65 years with SARS, and a mortality rate of 86.2% was published for individuals over 80 years of age with MERS ([@bib10]). An analysis of 72,314 COVID-19 cases by the China Centers for Disease Control showed a strong association between older age and mortality ([@bib13]). Although individuals under 50 years of age showed a case fatality rate less than 0.5%, mortality increased with each subsequent decade, to 1.3% in those aged 50--59 years up to 14.8% in individuals aged 80--89 years ([@bib13]). Furthermore, severe outcomes have been observed for both COVID-19 and MERS in individuals with comorbidities, such as chronic kidney disease or diabetes ([@bib13]). In contrast, cases in children appear to be rare and more mild, with asymptomatic cases and no deaths reported for children under 10 years of age ([@bib13]--[@bib15]).

Transmission and Prevention
===========================

Unique among the severe CoV outbreaks, SARS-CoV-2 appears to be efficiently transmitted person to person, including from individuals with minimal symptoms. Viral transmissibility is not as simple as the basic reproduction number, or R~0~, but it provides a clue to understand transmission potential. The early R~0~ for SARS-CoV-2 was estimated at 2.2, indicating that, on average, one individual would transmit the virus to 2.2 additional people ([@bib16]). The R~0~ for SARS-CoV (2003) was estimated as 3, but severe symptoms typically preceded transmission, thus facilitating epidemiological measures to control the pandemic ([@bib17]). In comparison, MERS infections have continued in Saudi Arabia over the past 8 years, without efficient human-to-human transmission (an R~0~ below 1), but with ongoing spillover events from camels sustaining the outbreak.

Epidemiological and social dynamics can further alter the transmission dynamics of an emergent virus. The incubation period of SARS-CoV-2 is estimated to be approximately 5 days (range, 1.3--11.3 d), and respiratory shedding in mild cases may be as long as 14 days, leading to the current 14-day quarantine recommendation ([@bib16]). The transmission of SARS-CoV-2 has been slowed by either broad-reaching limitation of personal movement and gatherings, as in China, or by aggressive contact tracing and isolation of suspect cases, as in South Korea. Both strategies result in a lower R~0~ and significant decline in COVID-19 cases. Importantly, early recognition of suspect cases is essential to limit transmission, particularly in hospital environments. Hospital employees comprised 29% of the individuals included in one of the early clinical case series, and 3.8% of those identified by records review, emphasizing the importance of early recognition and appropriate personal protective equipment (PPE) to protect healthcare workers ([@bib13], [@bib18]).

COVID-19 Clinical Course
========================

The clinical syndrome of COVID-19 can range between asymptomatic or mild illness (e.g., fever with or without cough) to severe respiratory distress, multiorgan failure, and death. Currently, 80% of cases are mild, 15% develop lower respiratory tract disease (i.e., worsening pneumonia), and 3--5% require intensive care. For those who progress to severe disease, the clinical course has an insidious onset, with minimal symptomatology progressing to worsening respiratory distress around Week 2 of illness ([@bib19]). Two case series have been published from hospitals in Wuhan detailing the clinical course of 99 patients at the Jinyintan hospital from January 1 through January 20, and 138 cases at the Zhongnan Hospital from January 1 through January 28, 2020 ([@bib18], [@bib19]). The vast majority of hospitalized patients presented with fever (83--99%) and a cough (59--82%), with 30% in each series having dyspnea on admission. In addition, a subset presented with only diarrhea and nausea as initial symptoms, potentially delaying recognition of infection ([@bib18]). In these series, 17--20% of admitted patients had ARDS, 11--13% required noninvasive ventilation, 4--12% required mechanical ventilation, and 3% were placed on extracorporeal membrane oxygenation ([@bib18], [@bib19]).

Radiologic findings, as described in the above case series and another series of 51 patients with COVID-19, demonstrated that the vast majority (≥90%) of these hospitalized patients had abnormalities on chest X-ray or computed tomography, usually bilateral ([@bib18]--[@bib20]). Computed tomography findings showed ground-glass opacities, with or without septal thickening, or consolidation, located predominantly in the peripheral or posterior lungs ([@bib20]). Later in the disease course (after 4 days as inpatient), imaging is more likely to show consolidation ([@bib20]).

Samples from bronchoalveolar lavage fluid appear to have higher viral loads than oropharyngeal washes ([@bib3]). With higher viral loads detected in deeper lung samples, intubation and bronchoscopy are suspected to be high-risk procedures for providers of patients with COVID-19, and therefore should be minimized as able and performed in an airborne isolation room under airborne precautions when necessary. Prevention of hospital-acquired infections will require aggressive screening, early recognition and diagnosis, and strict adherence to precautions, particularly for potentially aerosolizing procedures, such as intubation. The demands of airborne isolation precautions for any large number of patients can easily overwhelm medical systems with finite numbers of trained personnel, airborne isolation rooms, PPE, and dedicated equipment.

Therapeutics and Vaccines
=========================

There are no approved drugs or vaccines for hCoVs. Multiple vaccine candidates using different platforms are in preclinical development, and two have advanced to phase 1 clinical trials. Although this speed is unprecedented, progression through the necessary steps of development, safety testing, efficacy analyses, and manufacturing may take over a year until publicly available ([@bib21]). In the interim, rapid evaluation of potential therapeutics may provide an earlier intervention to mitigate disease. Antivirals targeting the RNA-dependent RNA polymerase (such as remdesivir) showed *in vitro* activity, as did the immune modulator, chloroquine ([@bib22]). The protease inhibitors, lopinavir and ritonavir, have been used, but they lack a clear antiviral mechanism for CoV proteases, and were ineffective in a controlled clinical trial ([@bib22]--[@bib24]). Clinical trials for remdesivir and hydroxychloroquine have begun, and additional therapeutics are in development ([@bib22]). Host-targeted therapeutics are also under consideration, including inhibitors of host proteases required for viral entry, or anti--IL-6 therapeutics that are hypothesized to blunt the cytokine storm in severe cases ([@bib25]). Based on evidence from SARS and MERS, current recommendations are to avoid the use of corticosteroids for patients with COVID-19 ([@bib26]). Corticosteroid use for patients with SARS-CoV was associated with higher plasma RNA levels at Weeks 2--3 into illness (reflecting likely prolonged viremia) and increased 30-day mortality (adjusted odds ratio, 26; 95% confidence interval, 4.4--154.8) ([@bib25]). Convalescent sera, including the neutralizing antibodies isolated from recovered cases, is a promising, but not yet scalable, option ([@bib27]).

Conclusions
===========

SARS-CoV-2 is the most recent emergent CoV, and having already demonstrated a greater facility for transmission than SARS-CoV or MERS-CoV, it threatens to be a devastating pandemic. Current recommendations to reduce transmission include: social distancing; hand hygiene; cough etiquette; and aggressive recognition and isolation and quarantine of cases and contacts. For the health care environment, early and judicious PPE use to prevent respiratory droplet and short-distance aerosol transmission, and appropriate environmental control of rooms housing patients, are critical. Although the majority of infections have been mild, hospitalized patients have high rates of complications, including the need for aggressive supportive care, including mechanical ventilation, continuous renal replacement therapy, and extracorporeal membrane oxygenation. These complications place a heavy burden on hospital systems that may be ill prepared for large numbers of patients who will require airborne isolation and prolonged durations of stay. There are no approved therapeutics, although there are some promising antivirals under study. Although the first severe CoV epidemic was halted by nonpharmacologic interventions alone, the COVID-19 outbreak has become a pandemic due to the efficient transmissibility of the virus. However, several countries have demonstrated that aggressive nonpharmacologic intervention and control measures can slow the spread, blunting the impact on the healthcare systems and allowing the time needed for the testing of potential therapeutics and vaccines. Beyond this pandemic, we must continue working toward sustained preparedness against future emergent infectious diseases.
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